SIGA Technologies(NASDAQ) SIGA

SIGA Technologies makes medicine to treat rare and dangerous viruses. The company helps governments protect people from health threats like smallpox. Its main product comes as a pill or an injection for medical emergencies.

Tools for Health Security

• Oral TPOXX: Pill formulated to treat human smallpox; delivered to the U.S. Strategic National Stockpile since 2013.
• IV TPOXX: Intravenous version of the antiviral approved by the Food and Drug Administration in May 2022.
• Supportive Services: Research, development, and manufacturing technology transfers provided to government agencies and partners.

Growth and Global Reach

• Signed an exclusive license and distribution deal with Hikma in March 2026 for the Middle East and North Africa.
• Modified the 19C BARDA contract in October 2023 to adjust how treatment courses are measured for intravenous products.
• Received $27.5 million in additional funding from government partners in 2025 for manufacturing and pediatric drug development.
• Fulfilled three procurement contracts for the U.S. Department of Defense totaling $28 million since 2022.

How SIGA Stays Prepared

The company uses a domestic supply chain in the U.S. to lower the risks of global trade disputes. This strategy includes producing the active ingredients and the final medicine within the country.

Key Financial Results

• Product and service revenues were $37.9 million for the three-month period ended June 30, 2026.
• International sales reached $13.0 million in the three months ended June 30, 2026, across two countries.
• Cash and cash equivalents totaled $117.6 million as of June 30, 2026.
• Net cash provided by operating activities was $6.5 million for the six-month period ended June 30, 2026.

Evolution of Health Defense

SIGA has transitioned into a commercial-stage company focused on national and international health security. Its specialized focus on antiviral treatments for rare diseases makes it a key partner for government stockpiling programs.